Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To describe the overall cancer-related healthcare utilization patterns, treatment patterns and outcomes in women diagnosed with platinum-sensitive recurrent high-grade serous ovarian cancer. Patients & methods: Subanalysis of the Spanish sample of a retrospective, noninterventional, multinational, observational study. Results: BRCA-mutated patients had better outcomes in terms of progression-free survival and overall survival than patients who were BRCA wild-type. It was observed that patients’ treatment outcomes after the first recurrence progressively worsened as the patient underwent subsequent chemotherapy lines. Healthcare resource utilization when accounting for the follow-up time did not substantially differ between BRCA1/2-mutated and BRCA wild-type patients. Conclusion: BRCA1/2 mutation carriers have better treatment outcomes, including longer survival, without a negative impact on the use of healthcare resources.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 68(6), 394–424 (2018).
2.
International for Research on Cancer (World Health Organization). The Global Cancer Observatory. Ovary (2019). https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf
3.
Sociedad Española De Oncología Médica. Las Cifras del Cáncer en España 2020. Sociedad Española de Oncología Médica (SEOM), Madrid, Spain (2020).
4.
Colombo N, Sessa C, Du Bois A et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger. Ann. Oncol. 30(5), 672–705 (2019).
5.
Matz M, Coleman MP, Carreira H et al. Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2). Gynecol. Oncol. 144(2), 396–404 (2017).
6.
Moschetta M, Boussios S, Rassy E, Samartzis EP, Funingana G, Uccello M. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going? Ann. Transl. Med. 8(24), 1710 (2020).
7.
Oza AM, Cook AD, Pfisterer J et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 16(8), 928–936 (2015).
8.
Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365(26), 2473–2483 (2011).
9.
Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J. Clin. Oncol. 37(27), 2437–2448 (2019).
• An interesting review on the management of patients with platinum-resistant, relapsed epithelial ovarian cancer.
10.
Bouberhan S, Pujade-Lauraine E, Cannistra SA. Advances in the management of platinum-sensitive relapsed ovarian cancer. J. Clin. Oncol. 37(27), 2424–2436 (2019).
11.
National Comprehensive Cancer Network. Ovarian Cancer. Including fallopian tube cancer and primary peritoneal cancer. Version 1.2020. March 11, 2020 (2020). https://www.nccn.org/professionals/physician_gls/default.aspx
12.
Konstantinopoulos PA, Lheureux S, Moore KN. PARP inhibitors for ovarian cancer: current indications, future combinations, and novel assets in development to target DNA damage repair. Am. Soc. Clin. Oncol. Educ. Book 40, e116–e131 (2020).
• An up-to-date review on the use of poly[adenosine diphosphate-ribose] polymerase inhibitors for the management of ovarian cancer.
13.
Cook SA, Tinker AV. PARP inhibitors and the evolving landscape of ovarian cancer management: a review. BioDrugs 33(3), 255–273 (2019).
14.
Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol. Oncol. 124(2), 347–353 (2012).
15.
González-Santiago S, Ramón YCT, Aguirre E et al. SEOM clinical guidelines in hereditary breast and ovarian cancer (2019). Clin. Transl. Oncol. 22(2), 193–200 (2020).
16.
Liu G, Yang D, Sun Y et al. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics 13(13), 1523–1535 (2012).
17.
Banerjee SN, Lord CJ. First-line PARP inhibition in ovarian cancer – standard of care for all? Nat. Rev. Clin. Oncol. 17(3), 136–137 (2020).
18.
Boussios S, Karihtala P, Moschetta M et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest. New Drugs 38(1), 181–193 (2020).
19.
Graña B, Lastra E, Llort G, Brunet J, Isla D. SEOM clinical guidelines for hereditary cancer. Clin. Transl. Oncol. 13(8), 580–586 (2011).
20.
Llort G, Chirivella I, Morales R et al. SEOM clinical guidelines in Hereditary Breast and ovarian cancer. Clin. Transl. Oncol. 17(12), 956–961 (2015).
•• In our setting and by the time this study was conducted, a key Spanish guidelines for the management of ovarian cancer.
21.
Moore K, Colombo N, Scambia G et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379(26), 2495–2505 (2018).
• A pivotal randomized clinical trial on the efficacy of olaparib as maintenance therapy in patients with newly diagnosed advanced high-grade serous or endometrioid ovarian cancer with a mutation in BRCA1, BRCA2 or both (BRCA1/2) who had a complete or partial clinical response after platinum-based chemotherapy.
22.
Capoluongo E, Ellison G, López-Guerrero JA et al. Guidance statement on BRCA1/2 tumor testing in ovarian cancer patients. Semin. Oncol. 44(3), 187–197 (2017).
23.
Capoluongo E, Scambia G, Nabholtz JM. Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus. Oncotarget 9(28), 19463–19468 (2018).
• Provides some considerations for incorporating genetic analysis of ovarian tumor samples into the patient pathway.
24.
Vos JR, Fakkert IE, De Hullu JA et al. Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition. J. Natl Cancer Inst. 112(2), 161–169 (2020).
25.
Gruppo Di Lavoro Aiom – Sigu – Sibioc – Siapec-Iap. Raccomandazioni per L'implementazione del Test BRCA Nelle Pazienti con Carcinoma Ovarico e Nei Familiari a Rischio Elevato di Neoplasia. V.2 – Gennaio 2019. Associazione Italiana di Oncologia Medica, Milan, Italy (2019). https://www.aiom.it/raccomandazioni-per-limplementazione-del-test-brca-nelle-pazienti-con-carcinoma-ovarico-e-nei-familiari-a-rischio-elevato-di-neoplasia/
26.
Delgado-Ortega L, Gonzalez-Dominguez A, Borras JM et al. The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study. Eur. J. Health Econ. 20(1), 135–147 (2019).
27.
Moya-Alarcón C, González-Domínguez A, Simon S et al. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. Clin. Transl. Oncol. 21(8), 1076–1084 (2019).
• A Spanish study to estimate the efficiency of providing germline BRCA1/2 testing to high-grade epithelial ovarian cancer patients without family history of ovarian cancer.
28.
Delgado-Ortega L, Gines Rubio J, Garcias De Espana MDC, Carcedo D, Cordero Puentes L, Moya De Alarcon C. Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain. Farm. Hosp. 42(3), 95–102 (2018).
• An important Spanish study to estimate the economic impact of the introduction of olaparib in the Spanish National Health System as maintenance monotherapy in patients with BRCA-mutation positive high-grade serous ovarian cancer.
29.
Unni SK, Schauerhamer MB, Deka R et al. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study. J. Ovarian Res. 9(1), 18 (2016).
30.
Marchetti C, De Leo R, Musella A et al. BRCA mutation status to personalize management of recurrent ovarian cancer: a multicenter study. Ann. Surg. Oncol. 25(12), 3701–3708 (2018).
31.
Oaknin A, Guarch R, Barretina P et al. Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Rev. Esp. Patol. 51(2), 84–96 (2018).
•• A key Spanish guideline on the use of biomarker testing in patients with epithelial ovarian cancer.
32.
Yu N, Xiao Y, Yi J, Oliveri D, Houghton R, Luhn P. Real world treatment patterns of patients with ovarian cancer receiving first line chemotherapy in the United States. Value Health 20(9), A473 (2017).
33.
Kim SI, Lee M, Kim HS et al. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. J. Ovarian Res. 12(1), 40 (2019).
34.
Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30(21), 2654–2663 (2012).
35.
Safra T, Rogowski O, Muggia FM. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int. J. Gynecol. Cancer 24(3), 488–495 (2014).
36.
Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol. Oncol. 146(1), 58–63 (2017).
37.
Safra T, Borgato L, Nicoletto MO et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol. Cancer Ther. 10(10), 2000–2007 (2011).
38.
Kwa M, Edwards S, Downey A et al. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin. Ann. Surg. Oncol. 21(5), 1468–1473 (2014).
39.
Gallagher DJ, Konner JA, Bell-Mcguinn KM et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann. Oncol. 22(5), 1127–1132 (2011).
40.
Hanker LC, Loibl S, Burchardi N et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann. Oncol. 23(10), 2605–2612 (2012).
41.
Ray-Coquard I, Pautier P, Pignata S et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381(25), 2416–2428 (2019).
42.
Gonzalez-Martin A, Pothuri B, Vergote I et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381(25), 2391–2402 (2019).
43.
Tyczynski J, Williams S, Gregory N et al. Real-world treatment patterns for platinum-sensitive recurrent serous ovarian cancer: findings from a multinational medical record review. J. Clin. Oncol. 33(Suppl. 15), e16548 (2015).
Information & Authors
Information
Published In
Pages: 13 - 27
PubMed: 34697945
Copyright
© 2021 The authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 7 June 2021
Accepted: 6 October 2021
Published online: 26 October 2021
Keywords:
Topics
Authors
Funding Information
AstraZeneca Farmacéutica Spain, S.A.
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients. (2021) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2021-0135
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Lucy Haggstrom, Yeh Chen Lee, Clare Scott, Philipp Harter, Linn Woelber, Jonathan Ledermann, Charlie Gourley, Iain A McNeish, Frédéric Amant, Isabelle Ray-Coquard, Alexandra Leary, Amit M Oza, Anna Tinker, Antonio González Martin, Sabrina Chiara Cecere, Sandro Pignata, Nicoletta Colombo, Hiroyuki Yoshida, Christian Marth, Ora Rosengarten, Kathleen Nadine Moore, Eva María Gómez-García, David Tan, Michael L Friedlander, How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes, International Journal of Gynecological Cancer, 10.1136/ijgc-2024-005976, 34, 12, (1932-1939), (2024).
- Mari Lahelma, Heini Rauhamaa, Riikka-Leena Leskelä, Outi Isomeri, Juhana Idänpään-Heikkilä, Sari Käkelä, Nichola Roebuck, Barbara Mascialino, Sakari Hietanen, Mikko Loukovaara, Annika Auranen, Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study, Acta Oncologica, 10.2340/1651-226X.2024.40324, 63, (763-771), (2024).